Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
LXRX has been the subject of a number of other research reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Wednesday, January 2nd. Citigroup reaffirmed a “buy” rating and set a $14.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, January 22nd. They noted that the move was a valuation call. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 5th. Finally, Wedbush set a $36.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, January 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $20.38.
Get Lexicon Pharmaceuticals alerts:
Shares of LXRX traded up $0.24 during trading hours on Tuesday, reaching $7.17. 807,934 shares of the company traded hands, compared to its average volume of 851,015. The firm has a market capitalization of $738.30 million, a P/E ratio of -5.65 and a beta of 0.63. Lexicon Pharmaceuticals has a 1-year low of $4.26 and a 1-year high of $13.97.
Several institutional investors and hedge funds have recently made changes to their positions in LXRX. Clearbridge Investments LLC raised its position in Lexicon Pharmaceuticals by 974,268.4% in the third quarter. Clearbridge Investments LLC now owns 1,295,910 shares of the biopharmaceutical company’s stock worth $13,827,000 after purchasing an additional 1,295,777 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in Lexicon Pharmaceuticals by 181.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock worth $1,783,000 after purchasing an additional 173,096 shares in the last quarter. Norges Bank acquired a new position in Lexicon Pharmaceuticals in the fourth quarter worth about $1,005,000. First Trust Advisors LP acquired a new position in Lexicon Pharmaceuticals in the third quarter worth about $1,525,000. Finally, Candriam Luxembourg S.C.A. raised its position in Lexicon Pharmaceuticals by 36.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 509,000 shares of the biopharmaceutical company’s stock worth $5,431,000 after purchasing an additional 137,000 shares in the last quarter.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Read More: Preferred Stock
To view ValuEngine’s full report, visit ValuEngine’s official website.